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Tscell/histiocytesrich large Bscell lymphoma (TCHRLBCL) was first described by Jaffe et al in 1984 as an unusual Bscell lymphoma mims
icking peripheral Tscell lymphoma.1 The lymphoma is 
uncommon and shares some morphologic and phenos
typic features with lymphocyte predominant Hodgkin 
lymphoma (LPHL).2,3 The two diseases, however, 
have different biological behavior.4 Morphologically, 
TCHRLBCL is a heterogeneous group of diseases 
that shows a spectrum of morphological changes.5 The 
lymphoma shows a diffuse pattern of nodal or extras
nodal involvement with a predominance of Tscells and 
histiocytes with a small number of single large Bscells 
(<10%). Some cases can occasionally express CDs30 
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BACKGROUnD: features of t-cell/histiocyte rich large b-cell lymphoma (thrlbcl) overlap with those of lym-
phocyte predominant hodgkin lymphoma (lphl). the two lymphomas may represent a spectrum of the same 
disease, and differentiation between the two can sometimes be difficult. We looked at histomorphologic, im-
munophenotypic and clinical information that may help differentiate the two entities.
METHODS: cases of thrlbcl and lphl were blindly reviewed and studied for histological pattern (nodular vs. 
diffuse), nuclear features and pattern of expression of cd20, cd30, cd57, epithelial membrane antigen (ema) 
and epstein-barr virus (ebV). a score encompassing diffuse histology, high nuclear grade, cd20 single-cell pat-
tern, cd30+, cd57-, ema-, and ebV+ was estimated for the diagnosis of tchrlbcl.
RESULTS: there were 58 cases, including 30 cases of tchrlbl and 28 cases of lphl. the median age was 36 
years for tchrlbcl and 21 years for lphl (P=0.0001). three types of nuclei were identified (lymphocytic/his-
tocytic, reed-Sternberg and centroblast-like). the latter two high-grade nuclei were suggestive of tchrlbcl. 
tchrlbcl and lphl, respectively, showed diffuse histology, 90% vs. 4% (P=0.001), single cd20+ cells, 93% 
vs. 3.5% (P=0.00004), cd30+ cells, 30% vs. 0% (P=0.01), cd57+ cells, 41% vs. 93% (P=0.008), ema+ cells, 
27% vs. 60% (P=0.113), ebV+ cells, 24% vs. 0% (P=0.117), high nuclear grade, 70% vs. 0% (P=0.001), total 
score 2-7 (mean 4.68) vs. 0-2 (mean 0.72) (P=0.001), high stage, 86% vs. 7% (P=0.0001). 
COnCLUSIOn: our findings indicate that a combination of multiple parameters can help differentiate between 
the two diseases. two cases originally diagnosed as lphl were re-assigned the diagnosis of thrlbcl.
and EpsteinsBarr virus (EBV).7s9 The lymphoma cells 
have been divided into three morphologic substypes: 
Lymphocytic/histiocytic (L&H) nuclei seen in LPHL, 
centroblastslike nuclei and ReedsSternbergslike nuclei.5 
Depending on the nuclear subtype these cells show difs
ferent surface marker expression. L&H cells can ocs
casionally express EMA, ReedsSternbergslike cells can 
occasionally express CD30 and centroblastslike nuclei 
can occasionally express Bcls2 and BcPs6.8 LPHL on 
the other hand shows a predominantly nodular pattern 
of growth with the L&H cells being the predominant 
neoplastic cells. The lymph nodes show patchy express
sion of large CD20 positive cells in a background of 
reactive CD20 positive small lymphocytes.10 They also 
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frequently express epithelial membrane antigen (EMA). 
CD57 expression in LPHL shows a characteristic ros
sette pattern of expression in the reactive perisneoplass
tic cells.11,12 Differentiation between TCHRLBCL and 
LPHL can sometimes be difficult.7,13,14 The differentias
tion between the two diseases is important since each 
disease has its own management strategy and prognosis. 
TCHRLBCL is, for the most part, an aggressive disease 
usually presenting in advanced stages whereas LPHL is 
an indolent disease that mostly presents in early stage.15 
TCHRLBCL usually requires aggressive chemotheras
py and usually shows a poor disease outcome. LPHL 
requires less aggressive therapy and usually has good 
survival.15,16 We studied cases of TCHRLBCL and 
LPHL to identify morphologic, phenotypic and clinical 
features of the two diseases that help differentiate them, 
especially in borderline cases. 
METHODS
All cases of TCHRLBCL and LPHL diagnosed in our 
institution between 1998 and 2005 were retrieved. The 
diagnosis of TCHRLBCL was based on the WHO cris
teria2 for the most part with some modification where 
the lymph nodes were diffusely effaced with a small 
number of CD20+ large cells identified in a background 
of T lymphocytes with or without histiocytic collecs
tions. The diagnosis of LPHL was based on the press
ence of a nodular nodal effacement with the presence of 
large L&H cells with the expression of CD20 in large 
nodules or patches of small cells intermixed with large 
CD20+ cells. Expression of CD57 in a rosette fashion 
in the reactive T cells and EMA in the malignant cells 
was indicative of LPHL. The original diagnosis was 
independently reached by one of the three lymphoma 
pathologists in the institution (AT, WAM and MO). 
The cases were then retrieved and blindly reviewed by 
another pathologist (WAM) without knowledge of the 
final diagnosis. Histological and immunphenotypic 
data were evaluated to see if the cases could be assigned 
to either the TCHRLBCL category or the LPHL cats
egory.
The cases were then evaluated morphologically 
and by immunohistochemistry. Morphologically, 
cases showing a diffuse growth pattern were more 
suggestive of TCHRLBCL whereas cases showing 
a nodular growth pattern were suggestive of LPHL. 
Immunohistochemical stains for CD10, CD 20, CD57, 
Bcls2, Bcls6, EMA and CD30 were performed accords
ing to the manufacturer’s procedure (Ventana Medical 
systems, Tucson, Arizona, USA). Inssitu hybridizas
tion for EBV for EBERs1 mRNA was also performed. 
Phenotypically CD20 expression in single cells was 
indicative of TCHRLBCL while large CD20 positive 
cells in a patchy background of reactive small Bslyms
phocytes was indicative of LPHL. Expression of EMA 
was in favor of LPHL and negative staining was more 
in favor of TCHRLBCL. The characteristic expression 
of CD57 in a diffuse fashion with rosette formation 
was suggestive of LPHL and the lack of such express
sion or scattered CD57 positive cells was suggestive of 
TCHRLBCL. Cases that had features more consistent 
with TCHRLBCL were given this diagnosis and those 
that showed more features of LPHL were designated 
as such.
A scoring system was used for each of the seven 
parameters (Table 1). The score ranged from 0 to 7. 
The higher the score the more likely the diagnosis of 
TCHRLBCL. Patient charts were blindly reviewed for 
staging of the disease and patients were divided into 
those who presented in low stage (Stage 1 and 2) and 
those who presented in high stage (Stage 3 and 4) diss
ease.The final diagnosis for the purpose of the study 
was rendered after a consensus meeting between the 
three lymphoma pathologists using the final score.
 Statistical analysis was by the Chissquare test of 
equality of proportions. Bonferroni’s correction was 
used to adjust for the multiple group comparisons.17
RESULTS
Fiftyseight cases were identified, including 30 cases of 
TCHRLBCL and 28 cases of LPHL. Originally there 
were 28 cases of TCHRLBCL and 30 cases of LPHL. 
The malesto femalesratio in TCHRLBC lymphoma was 
2.7 to 1 whereas it was 5 to 1 in LPHL. TCHRLBCL 
cases ranged in age from 3 to 97 years (median 36 
years) whereas LPHL cases ranged in age from 8 to 51 
years (median 21 years) (P=0.0001). Twenty cases of 
TCHRLBCL were referred from outside institutions. 
The correct diagnosis of TCHRLBCL was rendered 
in only 7 cases (35%). The other diagnoses included 
classical Hodgkin lymphoma (9 cases), peripheral Ts
cell lymphoma (2 cases) and lymphoma not otherwise 
specified (2 cases). Fifteen cases of LPHL were referred 
from outside institutions. The correct diagnosis of 
LPHL was rendered in only 7 cases (46.6%). Classical 
Hodgkin lymphoma was the commonest diagnosis rens
dered (11 cases), while others were reactive lymphoid 
hyperplasia (2 cases) and lymphoma not otherwise 
specified (2 cases). 
Histologically, a diffuse pattern of growth was seen 
in 27 of 30 (90%) cases of TCHRLBCL (Figure 1A) 
whereas it was seen in 1 of 28 (4%) cases of LPHL. 
A nodular growth pattern was seen in 3 of 30 cases of 
TCHRLBCL (10%) and in 27 of 28 (96%) cases of 
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Table	1.		Scoring system for seven histologic and immunophenotypic features.
Pattern Score Pattern Score
Histology nodular 0 Diffuse 1
CD20 patches intermixed with large cells 0 Single cells 1
CD30 negative 0 positive 1
eBV negative 0 positive 1
ema positive 0 negative 1
CD57 positive 0 negative 1
large cells l&H 0 rbS or Centroblastic 1
minimum score = 0; maximum score = 7
Figure	1.	a) Case of TCHrlBCl showing a diffuse growth pattern (H&e ×50). B) Case of THrlBCl showing single CD20+ cells 
(immunoperoxidase ×200). C) Case of TCHrlBCl showing scattered CD30+ large cells (immunoperoxidase ×200). D) Case of TCHrlBCl 
showing centroblasts  (H&e ×400). e) Case of TCHrlBCl showing reedbSternbergblike cells (H&e ×400). F) Case of TCHrlBCl showing 
l&H type cells (H&e ×100). G) Case of TCHrlBCl showing single CD20+ cells (immunoperoxidase ×200). H) Case of TCHrlBCl 
showing single cells expressing ema (immunoperoxidase ×200). i) Case of TCHrlBCl showing expression of CD57 in a rosette pattern 
similar to that seen in lpHl (immunoperoxidase ×200).
LPHL (P=0.0001; Figure 2A). CD20 expression in 
TCHRLBCL was characteristically different from that 
in LPHL. It mainly consisted of single cell expression 
in a background of T cells (Figure 1B). CD20 express
sion in LPHL was predominantly seen as a few CD20 
positive large (L&H) cells in a background of nodules 
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or patches of reactive small CD20 positive lymphos
cytes (Figure 2B). The TCHRLBCL pattern of exs
pression of CD20 was seen in 28 of 30 (93%) cases of 
TCHRLBCL and in 1 of 28 (3.57%) of LPHL cases 
(P=0.0004). CD30 expression was seen in 9 of 30 
(30%) of cases of TCHRLBCL (Figure 1C) and in 0 
of 28 cases of LPH with occasional background reacs
tive CD30+ cells (P=0.01). The characteristic rosette 
CD57 expression was seen in 12 of 30 cases (40%) of 
TCHRLBCL and in 26 of 28 cases (93%) of LPHL 
(P=0.008; Figure 2C). EMA expression was seen in 5 
of 30 cases (24%) of TCHRLBCL and in 17 of 28 cases 
(60%) of LPHL (P=0.113). EBV expression was seen 
in 4 of 30 cases (13%) of TCHRLBCL and 0 of 28 cass
es of LPHL (P=0.117). Highsgrade (centroblast and 
ReedsSternberg like) nuclei were seen in 21 of 30 cases 
(70%) of TCHRLBCL (Figures 1D and 1F) and in 0 
of 28 cases of LPHL (P=0.001). TCHRLBCL cases 
had a total score of 2 to 7 (mean 4.68) whereas LPHL 
had a score ranging from 0 to 2 with median of 0.72 
(P=0.0001; Figure 3). Cases of TCHRLBCL showing 
L&H type nuclei had the lowest scores (Figure 1F) and 
showed an EMA pattern of expression similar to that 
seen in LPHL (Figure 1H) with a pattern of CD57 exs
pression similar to LPHL (Figure 1I). However, they 
showed a diffuse growth pattern and singlescell express
sion of CD20 (Figure 1G). Using the above findings, 
the two cases originally diagnosed as LPHL were resass
signed the diagnosis of TCHRLBCL. Both cases had a 
score of more than 2 and had stage III and IV disease. 
High stage (Stage III and IV) disease was seen in 26 
of 30 cases (86%) of TCHRLBCL whereas it was seen 
in 2 of 28 cases (7%) of LPHL (P=0.0001). Table 2 
shows the morphologic, phenotypic and clinical finds
ings of TCHRLBCL and LPHL.
DISCUSSIOn 
TCHRLBCL is an aggressive lymphoma that usus
ally presents in an advanced stage, requires aggressive 
chemotherapy and in many instances proves fatal.8,16 
LPHL on the other hand is an indolent lymphoprolifs
Figure	2.	a) Case of lpHl showing a nodular growth pattern 
(H&e ×50). B) Case of lpHl showing large nodules of CD20+ 
small cells intermixed with a small number of larger CD20+ 
cells (immunoperoxidase ×200). C) Case of lpHl showing the 
characteristic CD57+ rosettes around the neoplastic cells 
(immunoperoxidase ×200).
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Table	2.		morphologic, immunophenotypic and clinical data for cases  of TCHrlBCl and 
lpHl.
TCHRLBCL LPHL P		VALUE
Diffuse histology                                   27/30 (90%) 1/28 (4%) 0.0001
CD20 (single cells)                  28/30 (93%) 1/28 (4%) 0.0001
CD30+                         9/30 (30%) 0/28 0.01
CD57+                           12/30 (40%) 26/28 (93%) 0.008
ema+   5/30 (24%) 17/28 (60%) 0.113
eBV+ 5/30 (24%) 0/28 0.117
High grade nuclei                                21/30 (70%) 0/28 0.001
age range (median) 
(years)                              3b96 (36) 8b51 (21) 0.0001
High stage (iii and iV) 25/29 (86%) 2/28 (7%) 0.0001
erative disorder that usually presents at an early clinis
cal stage, requires conservative therapeutic intervention 
and shows high survival.15 The two diseases may ocs
casionally show overlapping morphologic and immus
nophenotypic features. The term “grey zone lymphoma” 
indicates a group of lymphoproliferative disorders that 
shows overlapping features, making its proper classifis
cation sometimes difficult.3,18 These lymphomas mainly 
include classical Hodgkin lymphoma, TCHRLBCL, 
LPHL and Kis1 positive anaplastic large cell lyms
phoma. Proper typing of such lymphomas requires 
the concerted effort of expert lymphoma pathologists. 
Even in large institutions, difficulty in differentiating 
these lymphomas can arise. A study at MD Anderson 
Cancer Center showed that 18% of cases diagnosed 
as lymphocytesrich classical Hodgkin lymphoma were 
reclassified as TCHRLBCL after review.19 A large 
multisinstitutional study has shown that the diagnosis 
of LPHL could be confirmed in only 56% of the cases 
when reviewed by lymphoma experts.2 Another study 
has shown that up to 10% of all cases of TCHRLBCL 
in their series were diagnosed as LPHL.20 Our study 
has shown that a large number of cases of TCHRLBCL 
and LPHL referred to us were not correctly diagnosed. 
At the general practice level it is extremely difficult for 
general surgical pathologists who see a small number of 
lymphoma every year to be able to identify this group of 
borderline lymphomas. There is thus a need for criteria 
that general pathologists can use to identify lymphomas 
that show overlapping features. Histologically we have 
found in our study that the diffuse histology and the 
presence of centroblasts or ReedsSternbergslike cells 
are the most distinguishing histomorphologic features 
that help differentiate TCHRLBCL from LPHL. In 
one study, diffuse histology in cases diagnosed as LPHL 
was an independent predictor of recurrence.21 Those 
cases may have been cases of TCHRLBCL rather than 
LPHL. Difficult cases may require the use of several 
parameters to differentiate the two entities. The mors
phologic and immnophenotypic features of LPHL and 
TCHRLBCL are not consistently the same in all cases. 
Variations of the histologic and phenotypic profiles ocs
cur.10.12 A scoring system where several parameters that 
are known to differentiate between the two diseases can 
thus be used and may prove helpful.
Phenotypically, the pattern of CD20 expression in 
TCHRLBCL in single cells was one of the most distins
guishing features between the two diseases. Although 
the difference between TCHRLBCL and LPHL in the 
expression of CD30 and EBV was not statistically sigs
nificant, none of the cases of LPHL expressed CD30 
antigen or EBV mRNA. This suggests that CD30 and 
EBV can be used to exclude LPHL if either of two pas
rameters is positive.
Clinically TCHRLBCL usually shows a higher mes
dian age than LPHL.16 Studies have shown that the 
median age for TCHRLBCL is lower than the median 
age for diffuse large be cell lymphoma.20,22,23 We found 
that the median age difference between TCHRLBCL 
and LPHL is statistically significant. Additionally, the 
stage at presentation of TCHRLBCL was significantly 
higher than cases of LPHL. This has also been shown 
in other studies.18,22 Although there were some cases in 
our study of TCHRLBCL seen in young individuals 
and a rare case of LPHL that presented in high stage 
and age, clinical criteria can be used as a determins
ing factor for therapeutic decisions in differentiating 
TCHRLBCL from LPHL in difficult cases where mors
phologic and immunophenotypic data are inconclusive. 
Older patients with an advanced stage of an aggressive 
disease may be given the option of aggressive therapy 
when histomorphologic and phenotypic evidence is 
contrary to the clinical picture.
Our study as well as others have shown that despite 
the discriminating features, TCHRLBCL and LPHL 
have overlapping morphologic, phenotypic and clinical 
features. In our study THRLBCL showed L&H type 
nuclei in one third of the cases. Lim et al identified a 
similar incidence of L&H nuclei in their study.8 They 
found this type of nuclei in onesthird of their cases. In 
10% of our cases a nodular growth pattern was idens
tified in cases of TCHRLBCL. More than onesfourth 
of our cases of TCHRLBCL showed EMA expression. 
Other studies have shown that EMA can be expressed 
in cases of TCHRLBCL.24,25 Close to half of our cases 
of TCHRLBCL showed an expression pattern of CD57 
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similar to that seen in LPHL. These findings suggest, as 
previously suggested in other studies, that TCHRLBCL 
may represent more than one group of lymphoprolifers
ative disorders that share some biologic attributes with 
other lymphomas such as follicular lymphoma, classical 
Hodgkin lymphoma and LPHL.8,18 Our findings also 
suggest that TCHRLBCL and LPHL may, in some 
cases, represent one biologic continuum of the same 
disease. This subtype of cases may defy histomorphos
logic and phenotypic criteria and may require molecular 
studies to better define these two occasionally overlaps
ping diseases. Although some studies have shown diss
tinguishing molecular profiles of TCHRLBCL and 
LPHL,8,26,27 the technology is not available in most 
institutions. The use of clinical data, mainly age and 
stage at presentation, may help clinicians decide on the 
therapeutic approach when histomorphologic and phes
notypic data are not conclusive of the lymphoma type. 
The use of molecular profiling may eventually resolve 
these difficult differential diagnostic problems, but until 
such time the use of a scoring system utilizing morphos
logic, phenotypic and clinical characteristics may help 
resolve the differential diagnostic issues in most borders
line cases.
This study was presented in part in the United States and 
Canadian Academy of Pathology meeting in Vancouver, 
Canada, March 2004.
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